These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29800290)

  • 1. Optimizing carbapenem use through a national quality improvement programme.
    Robson SE; Cockburn A; Sneddon J; Mohana A; Bennie M; Mullen AB; Malcolm W; Armstrong J; Patton A; Seaton RA
    J Antimicrob Chemother; 2018 Aug; 73(8):2223-2230. PubMed ID: 29800290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme.
    Nathwani D; Sneddon J; Malcolm W; Wiuff C; Patton A; Hurding S; Eastaway A; Seaton RA; Watson E; Gillies E; Davey P; Bennie M;
    Int J Antimicrob Agents; 2011 Jul; 38(1):16-26. PubMed ID: 21515030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK.
    Gharbi M; Doerholt K; Vergnano S; Bielicki JA; Paulus S; Menson E; Riordan A; Lyall H; Patel SV; Bernatoniene J; Versporten A; Heginbothom M; Goossens H; Sharland M;
    BMJ Open; 2016 Nov; 6(11):e012675. PubMed ID: 27810974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing a baseline for a national paediatric antimicrobial stewardship programme.
    Gibbons CL; Malcolm W; Sneddon J; Doherty C; Cairns S; Milne A; Llano M; Reilly JS
    J Antimicrob Chemother; 2019 Oct; 74(10):3104-3110. PubMed ID: 31299069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study.
    Al Muqati H; Al Turaiki A; Al Dhahri F; Al Enazi H; Althemery A
    J Infect Public Health; 2021 Mar; 14(3):306-310. PubMed ID: 33618274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
    Yildirim I; Aytac S; Ceyhan M; Cetin M; Tuncer M; Cengiz AB; Secmeer G; Yetgin S
    Pediatr Hematol Oncol; 2008 Jun; 25(4):291-9. PubMed ID: 18484473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review.
    Petersen MW; Perner A; Sjövall F; Jonsson AB; Steensen M; Andersen JS; Achiam MP; Frimodt-Møller N; Møller MH
    Acta Anaesthesiol Scand; 2019 Aug; 63(7):973-978. PubMed ID: 31020663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
    Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB
    J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a Carbapenem Antimicrobial Stewardship Program on Patient Outcomes.
    Seah VXF; Ong RYL; Lim ASY; Chong CY; Tan NWH; Thoon KC
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate use of carbapenems in the Besançon university hospital.
    Jary F; Kaiser JD; Henon T; Leroy J; Patry I; Blasco G; Limat S
    Med Mal Infect; 2012 Oct; 42(10):510-6. PubMed ID: 23044084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem-resistant Klebsiella pneumoniae in Barbados: Driving change in practice at the national level.
    Forde C; Stierman B; Ramon-Pardo P; Dos Santos T; Singh N
    PLoS One; 2017; 12(5):e0176779. PubMed ID: 28542162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of appropriate carbapenem prescribing in stewardship programmes.
    Canouï E; Gauzit R; Bruneau A; Alviset S; Hays C; Charpentier J; Batista R; Kernéis S
    J Hosp Infect; 2018 Nov; 100(3):277-279. PubMed ID: 29614244
    [No Abstract]   [Full Text] [Related]  

  • 15. Development and evaluation of a national gentamicin and vancomycin quality improvement programme.
    Semple Y; Bennie M; Sneddon J; Cockburn A; Seaton RA; Thomson AH
    J Antimicrob Chemother; 2020 Jul; 75(7):1998-2003. PubMed ID: 32277830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A national quality incentive scheme to reduce antibiotic overuse in hospitals: evaluation of perceptions and impact.
    Islam J; Ashiru-Oredope D; Budd E; Howard P; Walker AS; Hopkins S; Llewelyn MJ
    J Antimicrob Chemother; 2018 Jun; 73(6):1708-1713. PubMed ID: 29506043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
    Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
    Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for More Rational Use of Antibiotics in Hospitalized Children in a Country With Low Resistance: Data From eight Point Prevalence Surveys.
    Thaulow CM; Berild D; Eriksen BH; Myklebust TÅ; Blix HS
    Pediatr Infect Dis J; 2019 Apr; 38(4):384-389. PubMed ID: 30882728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-time monitoring of antimicrobial use density to reduce antimicrobial resistance through the promotion of antimicrobial heterogeneity in a haematology/oncology unit.
    Murata S; Mushino T; Hosoi H; Kuriyama K; Kurimoto M; Watanuki J; Nishikawa A; Sonoki T; Nakakuma H; Hanaoka N
    J Antimicrob Chemother; 2015 Sep; 70(9):2661-4. PubMed ID: 26071518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.